...
首页> 外文期刊>Molecular cancer therapeutics >Src mediates cigarette smoke-induced resistance to tyrosine kinase inhibitors in NSCLC cells
【24h】

Src mediates cigarette smoke-induced resistance to tyrosine kinase inhibitors in NSCLC cells

机译:Src介导香烟烟雾诱导的NSCLC细胞对酪氨酸激酶抑制剂的抗性

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The EGF receptor (EGFR) is a proto-oncogene commonly dysregulated in several cancers including non- small cell lung carcinoma (NSCLC) and, thus, is targeted for treatment using tyrosine kinase inhibitors (TKI) such as erlotinib. However, despite the efficacy observed in patients withNSCLCharboring oncogenic variants of the EGFR, general ineffectiveness of TKIs in patients with NSCLC who are current and former smokers necessitates identification of novel mechanisms to overcome this phenomenon. Previously, we showed that NSCLC cells harboring either wild-type (WT) EGFR or oncogenic mutant (MT) L858R EGFR become resistant to the effects of TKIs when exposed to cigarette smoke, evidenced by their autophosphorylation and prolonged downstream signaling. Here, we present Src as a target mediating cigarette smoke-induced resistance to TKIs in bothWTEGFR- and L858RMTEGFR-expressing NSCLCcells. First, weshow that cigarette smoke exposure of A549 cells leads to time-dependent activation of Src, which then abnormally binds to the WT EGFR causing TKI resistance, contrasting previous observations of constitutive binding between inactive Src and TKIsensitive L858R MT EGFR. Next, we show that Src inhibition restores TKI sensitivity in cigarette smoke- exposed NSCLC cells, preventing EGFR autophosphorylation in the presence of erlotinib. Furthermore, we show that overexpression of a dominant-negative Src (Y527F/K295R) restores TKI sensitivity to A549 exposed to cigarette smoke. Importantly, the TKI resistance that emerges even in cigarette smoke-exposed L858R EGFR-expressing NSCLC cells could be eliminated with Src inhibition. Together, these findings offer new rationale for using Src inhibitors for treating TKI-resistant NSCLC commonly observed in smokers. Mol Cancer Ther; 12(8); 1579-90.
机译:EGF受体(EGFR)是原癌基因,通常在包括非小细胞肺癌(NSCLC)在内的几种癌症中失调,因此被靶向使用酪氨酸激酶抑制剂(TKI)如厄洛替尼进行治疗。然而,尽管在患有NSCLC的EGFR致癌变体患者中观察到了疗效,但现吸烟者和前吸烟者在NSCLC患者中TKIs普遍无效,因此有必要寻找新的机制来克服这一现象。以前,我们显示,携带野生型(WT)EGFR或致癌突变体(MT)L858R EGFR的NSCLC细胞在暴露于香烟烟雾时对TKI的作用具有抗性,这可通过其自身的磷酸化和延长的下游信号传递来证明。在这里,我们提出Src作为介导香烟烟雾诱导的表达WTEGFR和L858RMTEGFR的NSCLC细胞对TKIs的抗性的目标。首先,我们显示香烟暴露于A549细胞会导致Src的时间依赖性激活,然后Src异常结合到WT EGFR上,从而引起TKI耐药,这与先前关于非活性Src和TKI敏感L858R MT EGFR之间的本构结合的观察结果相反。接下来,我们显示Src抑制作用可恢复暴露于香烟烟雾中的NSCLC细胞中的TKI敏感性,从而在存在厄洛替尼的情况下防止EGFR自磷酸化。此外,我们显示显性负Src(Y527F / K295R)的过表达恢复了TKI对暴露于香烟烟雾中的A549的敏感性。重要的是,即使在香烟暴露的表达L858R EGFR的NSCLC细胞中出现的TKI耐药性也可以通过抑制Src消除。总之,这些发现为使用Src抑制剂治疗在吸烟者中常见的对TKI耐药的NSCLC提供了新的理论依据。分子癌疗法; 12(8); 1579-90。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号